MG
INSM icon

Michael Gelband’s Insmed INSM Stock Holding History

Michael Gelband’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$1.67M – 1826
2024
Q2 		$1.67M Hold
25,000
– – 0.01% 843
2024
Q1 		$680K Buy
+25,000
New +$700K 0.01% 1065

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Michael Gelband's INSM Position: Q2 2026 in Review

Michael Gelband reduced its Insmed (INSM) stake by 53% in Q2 2026, selling an estimated $9.52M and leaving 69,500 shares worth $7.41M. The position accounts for 0.05% of the portfolio, ranked #373.

Michael Gelband first reported a position in INSM in Q3 2019 and has held it in 17 quarters since. The position peaked at $24.2M in Q1 2026. 663 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • Michael Gelband held 69,500 shares of Insmed worth $7.41M as of Q2 2026.
  • Michael Gelband sold 78,633 Insmed shares in Q2 2026, an estimated $9.52M.
  • Insmed made up 0.05% of Michael Gelband's portfolio in Q2 2026, its #373 holding.
  • Michael Gelband first reported a position in Insmed in Q3 2019 and has held it in 17 quarters since.
  • Michael Gelband's Insmed position peaked at $24.2M in Q1 2026.
  • 663 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.